| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a06647c8ee341c0a68bed9988cdb30e6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efc66bdb9d93d73a8fe1667f7db87dbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afc27b52d9fdf35fa2697bbfd9105d3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb2df9c7252019c5edaf30bcdef4713a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0699743d8b21edcc3fbdb181b9c4bdee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5241a7de63e81e5e2543facdbcb58ff9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_650b27d5c5993240c9fb98c3986707d7 |
| publicationDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2016275210-B2 |
| titleOfInvention |
Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same |
| abstract |
The present invention relates to a heterocyclic compound having a novel structure that can be used in the prevention or treatment of diseases caused by abnormality in a PRS (prolyl- tRNA synthetase) activity, a method for preparing the same, and a pharmaceutical composition comprising the same. |
| priorityDate |
2015-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |